Optimizing the pretransplant regimen for autologous stem cell transplantation in acute myelogenous leukemia: better outcomes with busulfan and melphalan …
Autologous stem cell transplantation remains a clinical option to consolidate some adult
patients with acute myelogenous leukemia (AML) in first complete remission (CR1). In a …
patients with acute myelogenous leukemia (AML) in first complete remission (CR1). In a …
[PDF][PDF] Norbert Claude Gorin1| Myriam Labopin1| Didier Blaise2| Pierre-Yves Dumas3| Thomas Pabst4| Silvia Maria Trisolini5| William Arcese6|
M Houhou, M Mohty, A Nagler - academia.edu
Autologous stem cell transplantation remains a clinical option to consolidate some adult
patients with acute myelogenous leukemia (AML) in first complete remission (CR1). In a …
patients with acute myelogenous leukemia (AML) in first complete remission (CR1). In a …
Optimizing the pretransplant regimen for autologous stem cell transplantation in acute myelogenous leukemia: Better outcomes with busulfan and melphalan …
NC Gorin, M Labopin, D Blaise, PY Dumas… - American journal of …, 2018 - boris.unibe.ch
Autologous stem cell transplantation remains a clinical option to consolidate some adult
patients with acute myelogenous leukemia (AML) in first complete remission (CR1). In a …
patients with acute myelogenous leukemia (AML) in first complete remission (CR1). In a …
Optimizing the pretransplant regimen for autologous stem cell transplantation in acute myelogenous leukemia: Better outcomes with busulfan and melphalan …
NC Gorin, M Labopin, D Blaise… - American journal …, 2018 - pubmed.ncbi.nlm.nih.gov
Autologous stem cell transplantation remains a clinical option to consolidate some adult
patients with acute myelogenous leukemia (AML) in first complete remission (CR1). In a …
patients with acute myelogenous leukemia (AML) in first complete remission (CR1). In a …
Optimizing the pretransplant regimen for autologous stem cell transplantation in acute myelogenous leukemia: Better outcomes with busulfan and melphalan …
NC Gorin, M Labopin, D Blaise, PY Dumas… - American journal of …, 2018 - folia.unifr.ch
English Autologous stem cell transplantation remains a clinical option to consolidate some
adult patients with acute myelogenous leukemia (AML) in first complete remission (CR1). In …
adult patients with acute myelogenous leukemia (AML) in first complete remission (CR1). In …
Optimizing the pretransplant regimen for autologous stem cell transplantation in acute myelogenous leukemia: Better outcomes with busulfan and melphalan …
NC Gorin, M Labopin, D Blaise, PY Dumas… - American journal of …, 2018 - sonar.ch
English Autologous stem cell transplantation remains a clinical option to consolidate some
adult patients with acute myelogenous leukemia (AML) in first complete remission (CR1). In …
adult patients with acute myelogenous leukemia (AML) in first complete remission (CR1). In …
Optimizing the pretransplant regimen for autologous stem cell transplantation in acute myelogenous leukemia: Better outcomes with busulfan and melphalan …
NC Gorin, M Labopin, D Blaise, PY Dumas… - American Journal of …, 2018 - cir.nii.ac.jp
抄録< jats: title> Abstract</jats: title>< jats: p> Autologous stem cell transplantation remains a
clinical option to consolidate some adult patients with acute myelogenous leukemia (AML) in …
clinical option to consolidate some adult patients with acute myelogenous leukemia (AML) in …
Optimizing the pretransplant regimen for autologous stem cell transplantation in acute myelogenous leukemia: Better outcomes with busulfan and melphalan …
NC Gorin, M Labopin, D Blaise, PY Dumas… - American Journal of …, 2018 - europepmc.org
Autologous stem cell transplantation remains a clinical option to consolidate some adult
patients with acute myelogenous leukemia (AML) in first complete remission (CR1). In a …
patients with acute myelogenous leukemia (AML) in first complete remission (CR1). In a …